The results obtained using gene expression arrays and phosphoproteome analyses allowed us to identify relevant components of the Hippo signaling pathway as potential biomarkers of acquired resistance to trastuzumab in human HER2-positive breast-cancer cells. Here, ERBB2 is linked to breast carcinoma.